中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2015年
3期
41-42
,共2页
非小细胞肺癌%脑转移瘤%伽玛刀%疗效
非小細胞肺癌%腦轉移瘤%伽瑪刀%療效
비소세포폐암%뇌전이류%가마도%료효
Non-small cell lung cancer%Brain metastasis%Gamma knife%Efifcacy
目的:评价伽玛刀立体定向放射治疗非小细胞肺癌(NSCLC)脑转移瘤的疗效。方法回顾性分析接受伽玛刀治疗的43例非小细胞肺癌合并1~4个脑转移瘤患者的临床资料,根据转移灶情况确定治疗剂量,取50%~60%的等剂量曲线覆盖靶区,伽玛刀治疗剂量为16~20 Gy,评估局部控制率和生存率。结果43例患者中,完全缓解9例(20.9%),部分缓解23例(53.5%)例,疾病稳定10例(23.3%),有效率74.4%(32/43);6个月总的肿瘤局部控制率为90.7%(39/43)。全组患者的中位生存期为11个月(95%可信区间为7.2~14.8),6个月、1和2年总生存率分别为81.4%、46.5%和20.9%。未发现放射治疗相关致死病例。结论伽玛刀治疗非小细胞肺癌脑转移瘤疗效确切、安全。
目的:評價伽瑪刀立體定嚮放射治療非小細胞肺癌(NSCLC)腦轉移瘤的療效。方法迴顧性分析接受伽瑪刀治療的43例非小細胞肺癌閤併1~4箇腦轉移瘤患者的臨床資料,根據轉移竈情況確定治療劑量,取50%~60%的等劑量麯線覆蓋靶區,伽瑪刀治療劑量為16~20 Gy,評估跼部控製率和生存率。結果43例患者中,完全緩解9例(20.9%),部分緩解23例(53.5%)例,疾病穩定10例(23.3%),有效率74.4%(32/43);6箇月總的腫瘤跼部控製率為90.7%(39/43)。全組患者的中位生存期為11箇月(95%可信區間為7.2~14.8),6箇月、1和2年總生存率分彆為81.4%、46.5%和20.9%。未髮現放射治療相關緻死病例。結論伽瑪刀治療非小細胞肺癌腦轉移瘤療效確切、安全。
목적:평개가마도입체정향방사치료비소세포폐암(NSCLC)뇌전이류적료효。방법회고성분석접수가마도치료적43례비소세포폐암합병1~4개뇌전이류환자적림상자료,근거전이조정황학정치료제량,취50%~60%적등제량곡선복개파구,가마도치료제량위16~20 Gy,평고국부공제솔화생존솔。결과43례환자중,완전완해9례(20.9%),부분완해23례(53.5%)례,질병은정10례(23.3%),유효솔74.4%(32/43);6개월총적종류국부공제솔위90.7%(39/43)。전조환자적중위생존기위11개월(95%가신구간위7.2~14.8),6개월、1화2년총생존솔분별위81.4%、46.5%화20.9%。미발현방사치료상관치사병례。결론가마도치료비소세포폐암뇌전이류료효학절、안전。
Objective To evaluate the efficacy of patients with non-small cell lung cancer (NSCLC) and one to four lesions of brain metastasis (BM) undergoing gamma knife stereotactic radiotherapy.Methods Fourty-three patients with NSCLC and one to four BM lesions treated by gamma knife were eligible for this retrospective analysis. The dosage were established on the BM lesions. The dose carve was 50%-60% and covered the target volume. The dose of gamma kinfe was 16-20 Gy. Evaluate the local control rate and the overall survival.Results Of 43 patients, 9(20.9%) achieved complete response, 23(53.5%) achieved partial response, 10(23.3%) achieved stable disease. The overall response rate was 74.4%(32/43), and the six-month overall tumor control rate was 90.7%(39/43). The median survival time was 11 months(range: 3-30 months; 95% conifdence interval: 7.2-14.8). The six-month, one-year and two-year overall survival rates were 81.4%, 46.5% and 20.9%. No severe adverse events and toxicity were observed.Conclusion For patients with non-small cell lung cancer and brain metastasis treated by gamma knife SRT is safety and effective.